In both laboratory and animal testing, CUDC-305 demonstrated high potency in vitro and in vivo across a wide range of cancers. Tumor regression has also been observed after treatment of CUDC-305 in mouse xenograft models of breast, non-small cell lung, gastric cancer and glioblastoma brain cancers.
In addition to demonstrating potent efficacy across a broad range of cancers in preclinical cancer models, CUDC-305 exhibits promising pharmacological features, particularly its high oral bioavailability, high tumor penetration and extended tumor retention.
Dan Passeri, president and CEO of Curis, said: “We are pleased to enter this field with our own novel and proprietary compound, CUDC-305, which not only has met our rigorous internal metrics for development candidate selection, but has also demonstrated pharmacological properties that, while based upon early results, we believe may enable it to achieve best-in-class among Hsp90 inhibitors.”